Items tagged with Drug-susceptible TB
BOSTON — A shorter treatment regimen consisting of rifapentine, moxifloxacin, isoniazid and pyrazinamide was more active than a control regimen against drug-susceptible pulmonary tuberculosis, researchers reported at the 2014 Conference on Retroviruses and Opportunistic Infections.
TB Alliance, an international non-profit drug development organization that develops better, faster-acting, and affordable tuberculosis (TB) drugs, has announced that it is collaborating with, and has granted an exclusive license to, the Shanghai Fosun Pharmaceutical Development Co., Ltd., and its subsidiary Shenyang Hongqi Pharmaceutical Co., Ltd. (Fosun Pharma), to develop and commercialize the first-ever regimen designed to treat both drug-sensitive TB (DS-TB) and multi-drug resistant TB (MDR-TB) for use within People’s Republic of China, Taiwan, Hong Kong and Macau (Licensed Territory).
From total neglect till a few years ago, childhood TB is now taking centrestage. A couple of days back, the WHO released an updated guidance for national TB programmes (NTPs) on the management of tuberculosis in children.
Multidrug-resistant (MDR) tuberculosis is a public health emergency and a challenging scenario for both patients and clinicians. (1, 2). In 2012, there were more than 450 000 incident cases and 170 000 deaths worldwide (3).
Global Drug Facility reaches a 58% price reduction for Rifabutin by adding a new supplier to its product catalogue (post)
6, June 2014 – Geneva – The Stop TB Partnership Global Drug Facility (GDF) has achieved a near 60% reduction in the price of Rifabutin, by including a new supplier into its product catalogue.
A novel TB drug regimen could treat drug-sensitive and some forms of drug-resistant TB far more quickly than current standard TB therapy, according to findings from a phase IIb trial were presented today at the 20th International AIDS Conference (AIDS 2104) in Melbourne, Australia.
A combination regimen containing high-dose rifampin (also known as rifampicin) was associated with faster tuberculosis bacteria culture conversion in people with drug-sensitive TB, but moxifloxacin and the experimental drug SQ109 showed no benefit compared to standard therapy, according to results from a study presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
Some strains of multidrug resistant tuberculosis (MDRTB) may have a lower fitness (be less capable of spreading) than drug-susceptible tuberculosis bacteria, according to a study published this week in PLOS Medicine. The study, conducted by Louis Grandjean of Imperial College London, and colleagues, compared new tuberculosis cases among household contacts of tuberculosis patients in South Lima and Callao, Peru to determine the relative fitness of MDRTB versus drug-susceptible tuberculosis.
Community-based management versus traditional hospitalization in treatment of drug-resistant TB: a systematic review and meta-analysis (post)
The risk that patients with drug-susceptible tuberculosis will experience a relapse appears greater when minimum inhibitory concentration, or MIC, values are higher, according to study findings published in The New England Journal of Medicine.
Page 1 of 5 · Total posts: 01 2 Last→